Use of Febuxostat in Hyperuricemia Among Hemodialysis Patients

• Status: Completed
• Trial end date: 2017-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Hyperuricemia is not infrequently encountered among hemodialysis patients. However, there is no clear data about use of febuxostat among hemodialysis patients, apart from very small case series. The aim of this study is to investigate the efficacy of using febuxostat for the treatment of Hyperuricemia among hemodialysis patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Benha University
• Collaborator: New Jeddah Clinic Hospital
• Treatments: Febuxostat

Criteria

Inclusion Criteria:

• Age above 18 years

• Hemodialysis patient

• Hyperuricemia (Uric acid level above 6.0 mg/dL in females and 7.0 mg/dL in males)

Exclusion Criteria:

• Patient currently and/or recently received drugs for hyperuricemia within the last three months

• Patient had recent (within 3 months) change of erythropoiesis stimulating drugs or other drug known to increase uric acid e.g furosemide